Related Experiment Video
Updated: Apr 25, 2026
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Data on microRNA transcriptomic signatures, predicted gene targets and pathway analysis in response to cetuximab or
Laetitia Corset1, Frédéric Picou2,3,4, Frauke Beilstein2,3,4
1UMR CNRS INRAE 7247 PRC « Physiology of Reproduction and Behavior », France.
Abstract:
Resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAb) is common in metastatic colorectal cancer (mCRC) and reliable predictive biomarkers remain lacking. The identification of new predictive biomarkers is therefore necessary to assess the efficacy of anti-EGFR mAb, in order to optimize the therapeutic strategy for mCRC. Micro-RNAs (miR) are small non-coding RNAs that primarily regulate gene expression, and whose dysregulation in anti-EGFR resistance has been widely reported in CRC. Following a previous analysis using a miRnome strategy, the present study focused on NGS (next-generation sequencing) to investigate a broader range of miRNAs. We identified several miR resistance signatures as well as potential target genes and associated pathways following exposure to different doses of cetuximab or panitumumab in colorectal cancer cells. In the context of the search for useful biomarkers for this cancer, this could help optimize the design of in vivo experiments or future prospective clinical trials.
Insights
New micro-RNA (miR) signatures were identified as potential biomarkers for predicting resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAb) in metastatic colorectal cancer (mCRC). This research aids in optimizing treatment strategies and future clinical trials.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAb) is a significant challenge in treating metastatic colorectal cancer (mCRC).
- Current predictive biomarkers for anti-EGFR therapy efficacy in mCRC are insufficient, necessitating the discovery of novel markers.
- Micro-RNAs (miRs), small non-coding RNAs regulating gene expression, are implicated in anti-EGFR resistance in colorectal cancer (CRC).
Purpose of the Study:
- To identify novel micro-RNA (miR) signatures as predictive biomarkers for anti-EGFR mAb resistance in metastatic colorectal cancer (mCRC).
- To investigate potential target genes and pathways associated with miR-mediated resistance to anti-EGFR therapies.
- To optimize therapeutic strategies and guide future clinical trial designs for mCRC patients.
Main Methods:
- Utilized next-generation sequencing (NGS) to analyze a comprehensive range of micro-RNAs (miRNAs) in colorectal cancer cells.
- Exposed cancer cells to varying doses of cetuximab and panitumumab to simulate anti-EGFR therapy.
- Performed bioinformatic analysis to identify miR resistance signatures, target genes, and associated biological pathways.
Main Results:
- Identified several specific miR signatures associated with resistance to anti-EGFR monoclonal antibodies (mAbs) in colorectal cancer (CRC) cells.
- Discovered potential target genes and molecular pathways influenced by these miR resistance signatures.
- Demonstrated the utility of NGS in uncovering a broader spectrum of miRNAs involved in anti-EGFR resistance.
Conclusions:
- The identified miR signatures show promise as predictive biomarkers for anti-EGFR mAb efficacy in metastatic colorectal cancer (mCRC).
- Understanding miR roles in resistance can inform the development of more effective therapeutic strategies for mCRC.
- These findings support the optimization of in vivo experiments and prospective clinical trials for mCRC treatment.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs